Predictors for Recurrence of Atrial Fibrillation After Electrical Cardioversion

NCT03346863 | Unknown

• 1 other identifier: PRE-ELECTRIC 2017/1604
• Study Type: observational
• Target: 270
• Locations: 1 country
• Sites: 1

Brief Summary

In patients with persistent atrial fibrillation (AF), electrical cardioversion is very effective in restoring sinus rhythm if modern, biphasic cardioverters are used. However, approximately 50 per cent of the successfully cardioverted patients experience a recurrence of AF within a few weeks. Therefore, valid predictors for AF recurrence would be of great clinical relevance, to avoid unnecessary procedures. In the PRE-ELECTRIC study, we will investigate the predictive value of potential new biomarkers with respect to AF recurrence within 30 days after electrical cardioversion. We will investigate serum and plasma biomarkers, electrocardiological markers and echocardiographic variables in this respect. The study will be undertaken as a prospective cohort study at Bærum Hospital, Vestre Viken Hospital Trust, with national and international collaborators.

Conditions

Atrial Fibrillation

Keywords

Electrical Cardioversion

Outcome Measures

Primary Outcomes (1)

• Atrial fibrillation recurrence

  ECG-documented atrial fibrillation recurrence after successful cardioversion

  30 days after electrical cardioversion

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients \> 18 years referred for electrical cardioversion for ECG-documented persistent atrial fibrillation.

You may qualify if:

• Patients \> 18 years referred for electrical cardioversion for persistent atrial fibrillation
• Signed, informed consent

You may not qualify if:

• Patients \< 18 years
• Patients with paroxysmal atrial fibrillation
• Patients unwilling to participate or without consent competence

Sponsors & Collaborators

• Vestre Viken Hospital Trust: lead
• Oslo University Hospital: collaborator
• Lund University: collaborator

Study Sites (1)

Bærum Hospital, Vestre Viken

Sandvika, Bærum, 1346, Norway

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Serum, EDTA Plasma, Citrated Plasma, EDTA Whole Blood

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Arnljot Tveit, MD, PhD

CONTACT

0047-97171773; arnljot.tveit@vestreviken.no

Mona Olufsen, RN

CONTACT

0047-90637441; mona.olufsen@vestreviken.no

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 14, 2017
• First Posted: November 17, 2017
• Study Start: November 1, 2017
• Primary Completion: December 1, 2021
• Study Completion: December 1, 2023
• Last Updated: May 3, 2021

Record last verified: 2021-04

Data Sharing

• IPD Sharing: Will not share

Locations

NO (1)